A phase II trial of gemcitabine in a fixed dose rate infusion combined with cisplatin in patients with operable biliary tract carcinomas

Phase 2

Completed

• Conditions: Adenocarcinoma of the gallbladder or intra/extrahepatic bile ducts; Cancer - Biliary tree (gall bladder and bile duct)

• Registration Number: ACTRN12605000001695
• Lead Sponsor: AGITG/ NHMRC Clinical Trials Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-07-07
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Histologic or cytologic diagnosis of adenocarcinogen of the gallbladder or intra/extrahepatic bile ducts with locally advanced or metastatic disease that is not amenable to curative surgical resection or with recurrent disease after prior surgical resection or radiotherapy. Measurable disease.

Exclusion Criteria

No exclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified